Notes

Synthesis and Anti-anoxia Activities of 3-C Mono-substituted Cyclovirobuxine D Derivatives

  • Xiang Tao ,
  • Yang Hongjun ,
  • Chen Cheng ,
  • Feng Yuchuan
Expand
  • College of Chemistry & Environment Protection Engineering, Southwest University for Nationalities, Chengdu 610041

Received date: 2015-08-30

  Revised date: 2015-10-03

  Online published: 2015-10-13

Supported by

Project supported by the Southwest University for Nationalities Graduate Student Innovative Projects (No. CX2014SZ60), and the Fundamental Research Funds for the Central Universities (No. 2014NZYQN21).

Abstract

Seven novel cyclovirobuxine D derivatives were designed and synthesized by using cyclovirobuxine D as a starting material. All compounds synthesized were confirmed by 1H NMR, HRMS and IR. Preliminary results of anti-anoxia activity indicated that compounds displayed different degrees of activity, among them the compounds with piperazinyl exhibited higher anti-anoxia activity than others.

Cite this article

Xiang Tao , Yang Hongjun , Chen Cheng , Feng Yuchuan . Synthesis and Anti-anoxia Activities of 3-C Mono-substituted Cyclovirobuxine D Derivatives[J]. Chinese Journal of Organic Chemistry, 2016 , 36(2) : 432 -436 . DOI: 10.6023/cjoc201508030

References

[1] (a) Liang, B. W.; Deng, C. A.; Wang, X. B.; Hou, X. Q.; Tang, Y. Y. Chin. Pharmacol. Bull. 1981, 16, 3 (in Chinese). (梁秉文, 邓晨安, 王学斌, 侯晓清, 唐有元, 中国药学杂志, 1981, 16, 3.) (b) Xu, X. J.; Zhang, Z. X.; Sheng, L. S.; Liu, G. L.; An, D. K. Acta Pharm. Sin. 2002, 37(5), 395 (in Chinese). (徐新军, 张正行, 盛龙生, 刘皋林, 安登魁, 药学学报, 2002, 37(5), 395.) (c) Xu, X. J.; Zhang, Z. X.; Sheng, L. S.; Liu, G. L.; An, D. K. J. China Pharm. Univ. 2002, 33(5), 408 (in Chinese). (徐新军, 张正行, 盛龙生, 刘皋林, 安登魁, 中国药科大学学报, 2002, 33(5), 408.) (d) Hu, G. Q.; Xu, Q. T.; Zhang, B. G.; Huang, W. L. Chin. J. Nat. Med. 2004, 2(3), 155 (in Chinese). (胡国强, 许启泰, 张保国, 黄文龙, 中国天然药物, 2004, 2(3), 155.)
[2] Fang, T. H.; Xu, H. Q.; Xu, L.; Jin, S. E. China. Tradit. Herb. Drugs 1997, 28(7), 413 (in Chinese). (方泰惠, 许惠琴, 徐立, 金胜娥, 中草药, 1997, 28(7), 413.)
[3] Wang, Y. X.; Deng, Y. M.; Tan, Y. H.; Sheng, B. H. Acta Pharm. Sin. 1996, 31(7), 481 (in Chinese). (汪永孝, 郑云敏, 谭月华, 盛宝恒, 药学学报, 1996, 31(7), 481.)
[4] Hu, D.; Liu, X. Y.; Wang, Y. Y. Eur. J. Pharmacol. 2007, 569, 103.
[5] Lu, J.; Sun, D. P.; Gao, Y.; Ye, J. T. J. Pharmacol. Sci. 2014, 125, 74.
[6] Huang, D. D.; Lin, L.; Xu, L. Drug Res. 2014, 23(19), 26 (in Chinese). (黄丹丹, 林玲, 许立, 药物研究, 2014, 23(19), 26.)
[7] Huang, D. D.; Shao, L. J.; Xu, L. Her. Med. 2014, 33(12), 1562 (in Chinese). (黄丹丹, 邵靓婧, 许立, 药学导报, 2014, 33(12), 1562.)
[8] LIU, X. J.; Yao, M. H.; Fang, T. H. Acta Pharmacol. Sin. 1982, 3(2), 101 (in Chinese). (刘锡玖, 姚明辉, 方泰惠, 中国药理学报, 1982, 3(2), 101.)
[9] HU, S. L.; Zhou, L. H.; Fan, S. P. Acta Pharmacol. Sin. 1981, 2(2), 101 (in Chinese). (胡式冷, 周念辉, 范世潘, 中国药理学报, 1981, 2(2), 101.)
[10] Deng, L.; Huang, H.; Xu, M. X. Acta Pharm. Sin. 2006, 41(2), 121 (in Chinese). (邓兰, 黄衡, 徐鸣夏, 药学学报, 2006, 41(2), 121.)
[11] Deng, L.; Huang, H.; Xu, M. X.; Zhou, S. Q.; Ren, F.; Wang, X. W.; Li, D. Q. Acta Pharm. Sin. 2005, 40(9), 820 (in Chinese). (邓兰, 黄衡, 徐鸣夏, 周世清, 任昉, 王兴文, 李岱庆, 药学学报, 2005, 40(9), 820.)
[12] Deng, L.; Huang, H.; Xu, M. X.; Zhou, S. Q.; Wang, X. W. Chem. Res. Appl. 2005, 16(5), 623 (in Chinese). (邓兰, 黄衡, 徐鸣夏, 周世清, 王兴文, 化学研究与应用, 2005, 16(5), 623.)
[13] Deng, L.; Huang, H.; Xu, M. X.; Zhou, S. Q.; Wang, X. W.; Lu, M.; Ren, F.; Li, D. Q. Acta Pharm. Sin. 2004, 39(6), 434 (in Chinese). (邓兰, 黄衡, 徐鸣夏, 周世清, 王兴文, 卢淼, 任昉, 李岱庆, 药学学报, 2004, 39(6), 434.)
[14] Guo, C. H.; Yang, D. J.; Dou, H. S.; Fan, C. H.; Gao, N.; Li, Y.; Yin, S. F. Polym. Mater. Sci. Eng. 2006, 22(4), 72 (in Chinese). (郭彩虹, 杨定菊, 窦后松, 范辰华, 郜宁, 李颖, 尹述凡, 高分子材料科学与工程, 2006, 22(4), 72.)
[15] Guo, C. H.; Dou, H. S.; Gao, N.; Xiao, P. Y.; Li, Y.; Yin, S. F. West China J. Pharm. Sci. 2006, 21(6), 511 (in Chinese). (郭彩虹, 窦后松, 郜宁, 肖佩玉, 李颖, 尹述凡, 华西药学杂志, 2006, 21(6), 511.)
[16] Hu, C.; Yang, H. J.; Dou, H. S.; Li, Z. B.; Li, Y.; Yin, S. F. J. China Pharm. Univ. 2009, 40(1), 31 (in Chinese). (胡翠, 杨鸿均, 窦后松, 李正帮, 李颖, 尹述凡, 中国药科大学学报, 2009, 40(1), 31.)

Outlines

/